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Introduction
In this Supplementary material we give technical details regarding the detection, validation and characterization of novel human transcripts. First, we introduce ALTSCAN system in detail. Next, we give additional information for validation and consequent analysis described in the manuscript. Finally, we showed how the data mentioned in this paper would be accessed.
ALTSCAN
ALTSCAN (ALTernative splicing SCANner) is developed to find all possible exon-intron structure for coding genes. ALTSCAN incorporates transcriptional, translational, and splicing signals, together with length distributions of exons, introns and intergenic regions to predict multiple transcripts for each gene. When calculating the probability of a transcript, an extended Viterbi algorithm was utilized. Here we first presented details of ALTSCAN algorithms ( Figure S1 ), and then showed the processes of training and prediction. Figure S1 . ALTSCAN algorithm. ALTSCAN utilizes an extended Viterbi algorithm. Viterbi algorithm, which is a variation of dynamic programming, finds the most probable path in HMM/GHMM. A "trellis" is used to keep all the values in dynamic programming. A shows the "trellis" used in a traditional Viterbi algorithm. B shows the "trellis" used in ALTSCAN. A cell keeps an array of values instead of a single value, as shown in the enlarged view. The maximum top N values will be calculated from arrays of values and top N pointers will be kept. Finally, the most probable N paths will be reconstructed by tracing back. 
Algorithm
Generalized Hidden Markov Model (GHMM, also called Hidden Semi-Markov Model) has been utilized in gene structure prediction since 1997 1 . Compared with Hidden Markov Model (HMM), whose states follow geometric length distribution, GHMM supports general length distributions for its states. This is necessary for human gene structure prediction because of the non-geometric length distribution of its exons. On the other hand, the GHMM involves a more complex algorithm, requiring a recursion which searches back at each position over all possible previous positions. If the length of the sequence is L and the state number is N, then the computing complexity will be O(N 2 L 2 ). Obviously, the algorithm must be simplified due to the large size of L to make this approach practical. Burge proposed a simplified method 1 based on several assumptions: 1) States are grouped into 2 classes, coding states and non-coding states; 2) Coding states have durations less than D, and will be still treated using general length distribution; 3) Non-coding states follows geometric length distributions and sequence generating models which are "factorable", for instance, the emission probability E for type i to generate sequence s can be described as , where a, b and c are sequence positions and s x,y represents the sequence segment of sequence s from position x to y.
For HMM/GHMM model, the optimization problem is efficiently solved by the Viterbi algorithm. We first describe the problem here. For sequence , the model will give a "label" from the "label" space Ω to each position of the sequence. The label sequence can be described as , where
. The task is to find the "label" sequence to maximize the joint probability Pr(q, s). Before describing the optimization algorithm, we'll introduce some preliminaries:
( X represents the types (E/exon, N/intergenic region, P/promoter, I/intron, A/polyA).
y gives additional position information in gene structures (Einit/initial exon, Esingl/single exon, Eterm/terminal exon, Ein/ internal exon, Utr5/5' UTR, Utr3/3' UTR).
a represents the "phase" (p0/phase 0, p1/phase 1, p2/phase 2). Phase of coding state is defined as the number of base(s) at the head of the exon which is integrated with base(s) from adjacent upstream exon to form a "codon" when translated to protein. Phase of non-coding state is defined as the same phase as the upstream exon's.
s represents the strands, plus strand or minus strand. All the states have a strand mark except the state N (intergenic region).
(2) Transitions
The transition probability from state x to state y is denoted as , where On the other hand, the emission probabilities of non-coding states, Ψ , are modeled using a homogeneous fifth-order Markov matrix.
As described in the simplified method above, since state j ( Ψ ) follows a geometric length distribution, the probability of state j to generate the sequence segment differs from that of generating by a factor, , independent of a, which is the basis that we can treat non-coding states as in standard HMM in Viterbi algorithm.
(5) Initial probabilities
We force sequence start from non-coding states, therefore the initial probabilities of coding states are set as a non-zero value MIN_VALUE. The emission probability of non-coding state j is represented as Ψ . 6 Here, we first introduce our algorithm to predict the best gene structures (Top 1
Viterbi algorithm) based on this simplified method, and then introduce the extended algorithm (Top N Viterbi algorithm) with ability to predict the top N gene structures.
1) ALTSCAN Top 1 Viterbi algorithm
Top 1 Viterbi algorithm is based on a computation matrix , where n is the state number of the model and L is the sequence length. In this matrix, variables are defined as the optimal joint probability of the subsequence which ends in state n at position m. For coding states, m must be the exactly ending position of state n. These variables can be calculated recursively as follows:
Initialization:
Induction:
Termination:
Finally, tracing back from the maximum probability from , , we can obtain an optimal gene structure. In order to find the top N probable gene structures, we need to keep the best N probabilities at each cell of the computation matrix. It is to say, the computation matrix is enlarged to and variables are defined as the joint probability of the t th optimal parse of the subsequence which ends in state n at position m. These variables can be calculated recursively as follows:
Termination:
Finally, tracing back from the maximum N probability from , , we can obtain top N optimal gene structures.
Training and prediction
Refseq annotation was cleaned by removing genes with in frame stop codons with 
Evaluation
Refseq genes and GENCODE genes were combined as KNOWN dataset, which was used as a gold standard. protein-coding gene structures, so we didn't evaluate its specificity.
As described above, ALTSCAN used an extended multi-layer Viterbi algorithm. Here we showed this extended method indeed helped to find more transcripts. To see how much we were benefited from the predicted suboptimal structures, the KNOWN dataset was used as a gold standard. As shown in Figure S2 , with a traditional Viterbi algorithm for GHMM, which meant only the most probable structure was predicted for one input sequence (see Methods for more details), only 1,509 transcripts were found to be consistent with KNOWN transcripts. Overall, 84.6% of ALTSCAN transcripts consistent with KNOWN transcripts came from suboptimal paths, demonstrating that it was effective to predict alternative transcripts by including more suboptimal paths. 
Deficiency
ALTSCAN was used to find transcripts as many as possible, while it had several deficiencies. First, we applied ALTSCAN to candidate gene regions instead of the whole genome/chromosomes. Although we considered known protein-coding gene regions, predicted gene regions and regions only having EST supports, we might still miss potential protein-coding gene regions. Second, N=100 or even N=250 might not be deep enough. As shown in Figure S2 , there were still 14 transcripts found at each depth from 150 to 250, and this number didn't seem to go down. In addition, ALTSCAN didn't take rare splice signal, like GC-AG, into consideration. These deficiencies hindered ALTSCAN's exhausting protein-coding gene structures.
Dataset construction
In order to construct a comprehensive transcript dataset, we first collected transcripts from the GENCODE and RefSeq database. Then GENCODE and RefSeq transcripts 11 were combined and filtered. Transcripts sharing the same coding regions, having internal stop codons or short introns (<20bp) were removed. After filtering, the refined dataset was named KNOWN dataset, which represented all currently known transcripts. Then ALTSCAN dataset and KNOWN dataset were merged with redundant ones removed to form a MIXTURE dataset.
RNA-seq validation
RNA-seq data information
We collected 50 RNA-seq runs from the Illumina Human BodyMap2 project and ENCODE project. They were utilized to validate transcripts in the MIXTURE dataset (Table S1 ). Different runs of a biological sample were merged together as a single dataset. Finally, we obtained 26 datasets, which could be classified into to 3 groups:
GROUP I, data sequenced from a single tissue from the Illumina Human BodyMap2
project; GROUP II, data sequenced from a mixture of 16 tissues from Illumina Human BodyMap2 project; and GROUP III, data from ENCODE project. 
Validation strategies
Quality control of RNA-seq data were automatically processed using the NGSQC program with default parameters 14 . Coding sequences from MIXTURE transcripts were extracted with 100nts upstream start codons and 100nts downstream stop codons.
These coding fragments formed the mature transcript dataset. High quality reads were mapped to mature transcript dataset using Bowtie 15 with the option "-l 28 -n 2 -a --best".
We created a pipeline to validate candidate transcripts. For each transcript, we checked the coverage of all bases (full transcript coverage) and the coverage of all splice junctions (junction coverage). A base was covered if there was at least one read mapped to the position. We focused on validation of the splice sites of these transcripts. This wasn't to say transcription was not important. To balance this, we
give the rule that all the bases of a transcript should be covered at least once, which was quite loose, but effectively showed the transcription. A splicing junction site was covered if and only if at least M read(s) covered both sides of the adjacent exons with no less than L nt(s). Therefore, it was possible that a transcript was fully covered but not all the junctions were covered and vice versa. We developed multiple levels of validation criteria. For all transcripts (both single exon transcripts and multi-exon transcripts), full transcript coverage should be 100% in order to be called validated.
For multi-exon transcripts the junction coverage should be 100% as well. In this step, two strategies (the standard strategy and the stringent strategy) were used to check the junction coverage. In standard strategy, M was set to be 1 and L was set to be 10. In the stringent strategy, values of M and L depended on the RNA-seq data groups. We described how this was done in following parameter selection part.
In addition, additional rules were used to validate novel transcripts (in ALTSCAN but not in KNOWN dataset) in three levels, i.e. VHC (validation with high confidence) VMC (validation with median confidence) and VLC (validation with low confidence).
Multi-exon transcripts validated in stringent strategy with one or more novel internal splice junction sites (NIJ filter, see following and Figure S3 for details) were described as VHC transcripts; multi-exon transcripts validated in standard strategy with one or more novel internal splice junction sites were described as VMC transcripts; and multi-exon transcripts validated in standard strategy without novel internal splice junction sites, together with validated single-exon transcripts were described as VLC transcripts.
As shown in Figure S3 , there were two situations that validated transcripts had no novel internal splice junctions. The first situation was an alternative translational start sites and the second situation was an intron retention in the KNOWN transcripts.
These transcripts were also put into the VLC datasets. The remained transcripts with novel internal junctions would be put into the VHC transcripts. 
Parameter selection
Here we showed how we selected parameter M and L for stringent strategy. The sequencing depth and read length may impact on the selection of M and L. Therefore different datasets might need different parameters. Consider that different datasets from the same data group had the same sequencing lengths and the data size was quite 16 close, and to be comparable between validations from different datasets, we decided using the same parameters for datasets from a same group. Figure S4 ). 
Validation landscape
We validated MIXTURE transcripts with the pipeline and parameters described above.
The numbers of validated transcripts from each dataset were shown in Table S2 . By comparing validation of KNOWN and novel transcripts (Table S2) , we showed that novel transcripts have much higher levels of tissue-specific expression than KNOWN transcripts do (Table S3) . 
PCR validation
We randomly designed primers flanking novel splice sites for 88 VMC transcripts using Primer3. We ensured that primers were uniquely (at least 2 base mismatches for suboptimal alignments) mapped to human transcriptome or genome (hg19). We also ensured the product sizes were from 250 bps to 500 bps. Primer sequences were shown in Table S4 . 88 primers flanking novel splice sites and 8 primers flanking known splice sites from house-keeping genes were selected (Supplemental Table S4 ). 
Real-time PCR experiment
Real-time PCR validation was carried on in a range of tissues and cell lines. Table S5 ).
Specific target amplification (STA) was used to increase the number of copies of target cDNA. A 500 nM primer mixture (10x) was prepared by pooling 1 µL aliquots of all the primer pairs (100 µM) to be included in the STA reaction and the final volume adjusted to 100 µL. The pre-mix for the STA reaction was prepared by by the fragment analyser to ensure that the products fell within the expected range.
The 48 barcoded samples were pooled taking 1 µL from each sample, and purification of the sample pool was performed according to protocol. Briefly, Ampure XP beads were resuspended and 36 µL of the beads were added 12 µL of the pooled sample and 24 µL TE buffer. This solution was incubated at room temperature for 10 minutes and placed on a magnetic separator. The supernatant was discarded and beads were washed twice with 70% EtOH. The pellet was then air-dried for 10 minutes and resuspended in 40 µL DNA suspension buffer. The supernatant containing the cleaned fragments was transferred to a new tube.
The sample was analysed on the Agilent Bioanalyser to ensure that primers were successfully removed from the sample, and diluted to a final concentration of 2nM.
The sample was then denatured by incubating with 0.2 N NaOH for 5 minutes at room temperature. The denatured sample was further diluted to 10pM in pre-chilled HT1
(Hybridization Buffer provided in the MiSeq reagent kit) and spiked with 1-2%
Illumina PhiX control (Catalog # FC-110-3001) before loading on the MiSeq. 
Validation from sequencing results
Sequencing results were grouped by barcodes and qualified with Trimmomatic 16 .
Reads were mapped back to the mature transcripts with Bowtie. A successful validation of one splice sites requires: 1) each base of the target regions (defined by the primer pairs) was covered by at least 5 reads and 2) the junction sites were covered by at least 5 reads bridging at least 10 bases at each side. Each splice site was checked in 48 tissues. A-E showed 5 novel genes sharing the same splice junctions with previously annotated long non-coding RNAs. We found complete ORFs in these elements and showed their coding potentials. F showed a novel gene sharing a same splice site but different junctions with a previously annotated long non-coding RNAs. G showed a novel gene absent from GENCODE V12 but existing in GENCODE V17. Here we showed different splicing patterns. H showed a novel gene in the intron of gene RNU6-81P and its coding region was conserved. I showed a novel gene in the intron of DRAM2. This gene combined an L2 element and an LTR element. J showed a novel gene in the 3' UTR region of SHISA5.
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AS analysis
AS events are classified into seven categories: (1) exon skipping (cassette exons), an exon can be either included or excluded in the mature mRNA; (2) mutually exclusive exons, only one of the two or more adjacent exons can be included in the mature mRNA; (3) alternative splice acceptor sites; (4) alternative splice donor sites; (5) intron retention, where an intron can be either included or excluded in the mature mRNA; (6) alternative promoters (alternative first exons) and (7) alternative poly(A) (alternative last exons) [17] [18] [19] [20] . The frequency of each AS event category varies. From an evolutionary perspective, intron retention is the most common category in lower metazoans and is common in fungi and protozoa; while the frequency of exon skipping increases in the eukaryotes 17, 19 . In addition, exon skipping was considered to contribute most to the complexity of the proteome 17, 19 . Alternative splice donor and acceptor sites are believed to be subfamilies of exon skipping and may represent an intermediate evolutionary stage.
We introduced 11,549 confident transcripts (after pseudo-transcripts were removed from the 11,722 VHC transcripts) and the majority came from known genes as we described above. Therefore we found more alternative transcripts for known genes. In addition, there are still 5,166 (29.9%) multi-exon genes with only one transcript in KNOWN dataset, and we found an alternative isoform for 488 of these 5,166
transcripts. We also checked the novel splice events (see Detections of AS events part for details) and found that cassette exons, alternative translation stop sites and alternative translation start sites contributed most (Table S6) . Other events also involve a group of (at least 2) splice sites (see Supplemental materials for details).
Detection of AS events
Alternative splicing events are classified into seven categories: (1) 
GO/KEGG analysis
GO analysis
A background function distribution is important for GO analysis. We checked the distribution of GO functions in KNOWN datasets and KNOWN+VHC or KNOWN+VMC datasets. Coding sequences of transcripts were first translated into protein sequences, then the protein sequences were aligned to the GO database using the NCBI blastp 2.26+. Only those alignments with E value ≤ 1e-5, identity≥30% and coverage of the query sequence ≥25% would be considered as matches. Sequences were first aligned to human proteins in GO database, and sequences failed to align to human proteins were then aligned to proteins of other species.
The comparison of distributions of GO functions were shown in Figure S8 . 
Enrichment analysis
We checked if AS was enriched in some specific pathways or functions using KEGG 21 and GO annotation. KNOWN genes and ALTSCAN VMC genes were merged and then ranked by their transcript number. Enrichment analysis for the top quarter genes with the higheast number of transcripts (transcript number >5) were carried out with DAVID 22 . No significant enrichment were found in KEGG pathways. Enriched GO functions (adjusted p value with benjamini-hochberg method < 0.05) were shown in Table S7 . 
